Noxon, a Munich-based MedTech company and spin-off from three renowned universities, has successfully completed a seed funding round.
The round was led by High-Tech Gründerfonds (HTGF) and Bayern Kapital, two of the leading venture capital investors in Germany and Europe, together with Auxxo and another institutional investor. The funds will be used for the further development and clinical certification of Noxon’s non-invasive muscle-computer interface and for preparing the market launch of its first therapy modules.
In rehabilitation and in the treatment of neuromuscular diseases, muscle diagnostics and activation are currently mostly performed only sporadically and under clinical conditions. As a result, continuous data and adaptive therapy throughout the entire course of treatment are lacking in everyday practice.
Noxon closes this gap in care with a medical muscle-computer interface that, for the first time, combines continuous muscle diagnostics and neuromuscular electrical stimulation (NMES) in a user-friendly wearable device. Its unique selling proposition lies in the closed feedback loop of real-time measurement and personalized muscle and nerve activation throughout the course of therapy, as well as in its seamless integration with existing products such as tapes, patches, and orthopedic aids.
Furthermore, Noxon is collaborating with renowned medical partners, including the University Hospital of Würzburg and the neuroscience group N-Squared Lab, on additional pilot applications. The focus is on approaches that specifically support muscle control when signal transmission from the brain to the muscle is impaired. These include, for example, solutions for reducing tremor in Parkinson’s patients.
Maria Neugschwender, CEO of Noxon, said: “Neurological and musculoskeletal diseases are increasing worldwide. Healthy muscle function is fundamental, yet it remains a blind spot for many, and existing solutions are often too complicated or too expensive. The support from HTGF and Bayern Kapital enables us to further clinically validate our platform technology and launch our first products. Our goal is to make muscle health transparent, personalized, and affordable for everyone.”
Dr. Lena-Sophie Schütter, Investment Manager at HTGF, says: “What convinces me about Noxon is that effective therapy becomes as simple as putting on a bandage. The Muscle Computer Interface platform gives patients the chance to regain mobility and shape their everyday lives independently, from preventing muscle atrophy to reducing tremor in Parkinson’s disease. That’s a real step forward for quality of life.”
Monika Steger, Managing Director of Bayern Kapital, adds: “Noxon’s technology platform, which allows human muscles to be ‘read’ and then stimulated and activated, has significant potential in various fields of application, especially, of course, in therapy and medical rehabilitation. Potentially, this could enable faster and therefore gentler treatment of various currently difficult-to-treat diseases or injuries, such as Parkinson’s or paralysis. This would represent great added value for both medical technology and the healthcare sector. For us, Noxon is therefore a very promising investment.”
